1. Genesis, 9: 19-25.
2. Norström T. The Impact of Per Capita Consumption on Swedish Cirrhosis Mortality. British Journal of Addiction 1987; 82: 67-75
3. Pequignot G, Tuyns AJ, Bertha JL. Ascitic cirrhosis in relation to alcohol consumption. Int J Epidemiology 1978; 7: 113-120
4. Roizen R, Kerr WC, Filmore KM. Cirrhosis mortality and per capita consumption of distilled spirits. United States 1947-94: trend analysis.
British Medical Journal 1999; 319: 666-70
5. Kerr WC, Fillmore KM, Marvy P. Beverage-specific alcohol consumption and cirrhosis mortality in a group of English-speaking beer-drinking countries. Addiction 2000; 9: 339-346
6. Gruenewald PJ, Ponicki WR. The Relationship of Alcohol Sales To Cirrhosis Mortality. J Stud Alcohol 1995; 56: 635-641
7. Substance Abuse and Mental Health Administration. Results from the National Survey on Drug Use and Helth: National findings. Office of Applied Studies, NSDUH Seried H-28, DHSS publication no. SMA 05-4062. Rockville, Maryland: Substance abuse and Mental Health
Administration; 2005.
8. Batey RG, Burns T, Benson RJ, Byth K. Alcohol consumption and the risk of cirrhosis. Med J Aust 1992; 156: 413–416.
9. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992; 136: 1248–1257
10. Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose-response or threshold effect. J Hepatol 2004; 41: 25–30
11. Corrao G, Baghardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prevent Med 2004; 38:
613–619
12. Willner IR, Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2005;
21: 323–330
13. Meyerhoff DJ, Bode C, Nixon SJ, et al. Health risks of chronic moderate and heavy alcohol consumption: how much is too much? Alcoholism Clin Exp Res 2005; 29: 1334–1340
14. US Department of Health and Human Services. Dietary Guidelines for Americans 2005. US Department of Agriculture, HHS publication no. HHS-ODPHP-2005-01-DGA-A. Home and Garden bulletin no. 232. Washington DC: US Government Printing Office; 2005
15. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States.
Gastroenterology 2005; 128: 24–32
16. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States.
Gastroenterology 2005; 129: 1928–1936
17. Inoue M, Yoshimi I, Sobue T, Tsugahi S, JPHC Study Group. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a
prospective study in Japan. J Natl Cancer Inst 2005; 977: 293–300
18. Corrao G, Bagnardi V, Zambon A, Torchio P.Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998; 33: 381-392
19. Belletani S, Saccoccio G, Costa G Tiribelli C, Manenti F, Sodde M, Saveria Croce L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997; 41: 845-50
20. Becker U, Gronbaek M, Johansen D, Sorensen TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002; 35: 868-875
21. Klatsky and M.A. Armstrong, Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992;136: 1248–1257
22. Corrao G, Zambon A, Bagnardi V, Arico S, Loguercio C, D'Amicis A;
Collaborative SIDECIR Group. Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: an explorative case-control study. Eur J Epidemiol.
2004; 19: 861-869
23. Ramstedt M. Per capita alcohol consumption and liver cirrhosis mortality in 14 European countries. Addiction 2001; 96 (Supplement): s19-s34
24. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006; 367: 52-56
25. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain, 1950 to 2002. Lancet 2006; 367: 645
26. Kreitman N, Duffy J. Alcoholic and Non-alcoholic Liver Disease in Relation to Alcohol consumption in Scotland, 1978-84. Part I:
Epidemiology of Liver Diseases. British Journal of Addiction 1989; 84:
607-618
27. Lúdvíksdóttir D, Skúlason H, Jakobsson F, Thórisdottir A, Carigila N, Magnussón B, Thjodleifsson B. Epidemiology of liver cirrhosis morbidity and mortality in Iceland. European Journal of Gastroentrology &
Hepatology 1997; 9: 61-66
28. Noble JA, Caces MFE, Steffens RA, Stinson FS. Cirrhosis Hospitalization and Mortality Trends, 1970-87. Public Health Reports 1993; 108, 2: 192-197
29. Smith I, Burvill PW. Epidemiology of liver cirrhosis morbidity and
mortality in Western Australia, 1971-82: Some preliminary findings. Drug and dependence 1985; 15: 35-45
30. Poikolainen K. Increase in Alcohol-Related Hospitalizations in Finland 1969-1975. British Journal of Addiction. 1980; 75: 281-291
31. Mendez-Sanchez N, Villa AR, Chavez.-Tapica NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico form 2005 to 2050 through mortality data. Ann Hepatol 2005; 4:
52-55
32. Ramstedt M. Alcohol consumption and liver cirrhosis mortality with and without mention of alcohol – the case of Canada. Addiction 2003, 98: 1267-1276
33. Adang RP, Wensing WM, Stockbrugger RW. Alcohol consumption and alcohol-related liver disease in the Netherlands. Scand J Gastroenterology 1998; 33 Supplement 225: 70-74
34. Kerr WC, Fillmore KM, Marvy P. Additional comments on the aggregate-level associations between spirits consumption and cirrhosis mortality.
Addiction. 2000; 95: 1271-1272
35. Gronbaek M, Jensen MK, Johansen D, Sorensen TI, Becker U. Intake of beer, wine and spirits and risk of heavy drinking and alcoholic cirrhosis.
Biol Res. 2004; 37: 195-200
36. Everhart JE In vino Veritas. J Hepatol 2003; 28: 245-46
37. Pelletier S, Vaucher E, Aider R, Martin S, Perney P, Balmès JL Nalpas B Wine consumption is not associated with a decreased risk of alcoholic cirrhosis in heavy drinkers. Alcohol Alcohol 2002; 37: 618-621
38. http://www.systembolaget.se/NR/rdonlyres/25DDE957-9727-4A99-B932-B30077298C23/0/arsredovisning_04_eng.pdf, accessed May 10th 2006.
39. http://www.can.se/docs/press_rapporter/CAN_RS_79.pdf, accessed May 10th 2006
40. Kuhlhorn E, Ramstedt M, Hibell B, Larson S, Zetterberg, Swedish
consumption of alcohol from legal and illegal sources in the middle of the 1990s, Department of Health and Social Affairs, Stockholm, Sweden
41. Norstrom T, Estimating changes in unrecorded alcohol consumption in Norway using indicators of harm. Addiction. 1998; 93: 1531-1538
42. http://www.beroendecentrum.com/pages/topmenu/formular/audit.pdf, Accessed May 10th 2006
43. Bergman H, Kallmen H. Alcohol use among Swedes and a psychometric evaluation of the alcohol use disorders identification test. Alcohol Alcohol.
2002; 37: 245-251
44. Reed DN, Saxe A, Montanez M, Kotlowski R, Brancheau DA, Coffey DC, Pollard M, Fitzgerald H, Barber K, Wolf B. Use of a single question to screen trauma patients for alcohol dependence. J Trauma. 2005; 59: 619-23
45. Skinner HA. Instructions for the lifetime drinking history. Alcohol Research Foundation, Toronto Canada 1982
46. Lemmens P: Gebruik van bier, wijn, sterke drank. personal communication, 1997
47. Friesma HM, Veenstra, MY, Zwietering PJ, Knottnerus JA, Garretsen HFL;
Lemmens PHHM. Measurement of Lifetime Alcohol Intake: Utility of a self-administrated Questionnaire. American Journal of Epidemiology 2004;
159: 809-817
48. Lemmens PH: Measuring Lifetime Drinking Histories. Alc Clin Exp Res 1998; 22: 29S-36S
49. Summers T. Validity of alcoholics’ Self-Reported drinking History. Qart J Stud Alc 1970; 31: 972-974
50. Yates W, Labreque DR, Pfab D. The Reliability of alcoholism history in patients with alcohol-related cirrhosis. Alcohol Alcohol 1998; 33: 488-494
51. Corrao G, Arico S, Lepore AR, Valenti M, Torchi, P, Galatola G, Tabone M, DiOrio F. Amount And Duration Of Alcohol Intake As Risk Factor Of Symptomatic Liver Cirrhosis: A Case-Control Study. J Clin Epidemiol 1993, 46: 601-607
52. Corrao G, Torchio P, Zambon A, Ferrari P, Arico S, di Orio F. Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus infections on the risk of symptomatic liver cirrhosis. European Journal of Epidemiology 1998;14: 447-456
53. Donato F, Tagger A, Gelatti U, Pariello G, Boffetta P, Alberitni A, Decarli A, Trevisi P, Ribero L, Martelli D, Porru S, Nardi G. Alcohol and
Heaptocellular Carcinoma: The effects of Lifetime Intake and Hepatitis Virus Infection in Men and Woman. Am J Epidem 2002; 155: 323-331
54. Westin J, Lagging M, Spak F, Aires N, Svensson E, Lindh M, Dhillon A, Norkrans G, Wejståhl R. Moderate alcohol intake increases fibrosis
progression in untreated patients with hepatitis C virus infection. Journal of Viral Hepatitis 2002; 9: 235-241
55. Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M.
Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol. 2004 Jan; 99: 76-81
56. Ahmad S, Rohrbaugh JW, Anokin AP, Sirevaag EJ, Goebel JA. Effects of ethanol consumption on postural control: A computerized dynamic
posturography study. Journal of Vestibular Research 2002; 12: 53-64
57. Ji BT, Gao Y-T, Hsing AW, McLaughlin JK, Fraumeni Jr. JF, Chow W-H.
Cigarette and alcohol consumption and the risk of colorectal cancer in Shanghai, China. European Journal of Cancer Prevention 2002; 11: 237-244
58. Tjönneland A, Christensen J, Thomsen B, Olsen A, Stripp C, Overvad K, Olsen JH. Lifetime Alcohol Consumption and Postmenopausal Breast Cancer Rate in Denmark: a prospective Cohort Study. Journal of Nutrition 2004; 134: 173-178
59. York JL, Hirsch JA. Association between blood pressure and lifetime drinking patterns in moderate drinkers. Journal of Studies on Alcohol. 1997;
58: 480-485
60. International Classification of diseases Eight Version, WHO, 1966.
61. International Classification of diseases Ninth Version, WHO, 1987.
62. International Classification of diseases, Tenth Version, WHO, 1997.
63. Diagnostic and Statistical Manual of Mental Disorders, Washington DC, American Psychiatric Association, 1994
64. Dennis L. Kasper, Eugene Braunwald, Anthony S. Fauci, Stephen L.
Hauser, Dan L. Longo, J. Larry Jameson, and Kurt J. Isselbacher, Eds. In Harrison’s Principals of Medicine, Ch 289, Cirrhosis and its
complications16th Edition, McGrawHill 2006, through Harrison Online:
http://www.accessmedicine.com.proxy.kib.ki.se/content.aspx?aID=92107, accessed May 10th 2006
65. Miller LS, Kim JK, Dai Q, Mekapati J, Izanec J, Chung C, Liu JB,
Sanderson A, Bohning M, Desipio J, Gandegok J, Harberson JJ, Schneck C, Nicosia MA, Thangada V, Thomas B, Copeland B, Miller E, Miller A, Ahmed N, Brasseur JG. Mechanics and hemodynamics of esophageal varices during peristaltic contraction. Am J Physiol Gastrointest Liver Physiol. 2004; 4: G830-835
66. D’Amico G, Lucas A. Natural history. Clinical-hemodynamic correlations.
Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997; 11:
243-256
67. Graham DY, Lacey Smith J. The course of patients after variceal hemorrhage, Gastroenterology 1981; 80: 800-809
68. Iouannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage, the Cochrane database of Systemic Reviews, Volume 4, 2004
69. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis, (comment) Gastroenterology 2002;
123: 1013-1019.
70. Wung S, Sung JJ. Update on treatment of variceal hemorrhage. Digestive Diseases 2002; 20: 134-144
71. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R.
Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-9
72. McCormick PA, O’Keefe C. Improving prognosis following a first variceal hemorrhage over four decades. Gut 2001; 49: 682-685
73. El-Serag HB, Everheart JE. Improving prognosis after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. American Journal of Gastroenterology 2000; 95: 3566-3573
74. Chalasani N, Kahi C, Francois F, Pinto A, Marathe A, Bini EJ, Pandya P, Sitaraman S, Shen J. Improved Patient Survival After Acute Variceal Bleeding: A Multicenter Cohort Study. American Journal of
Gastroenterology 2003; 98: 653-659
75. Reuben, A. Alcohol and the Liver. Curr Opin Gastroenterol 2006; 22: 263-271
76. Iseri, OA, Gottlieb, L S, Lieber, C. S. The ultrastructure of ethanol-induced fatty liver. Fed. Proc. 1964; 23: 579A
77. Iseri OA, Lieber, CS, Gottlieb, LS. The ultrastructure of fatty liver induced by prolonged ethanol ingestion. Am. J. Pathol. 1966; 48: 535–555
78. Lane, BP, Lieber, CS. Ultrastructural alterations in human hepatocytes following ingestion of ethanol with adequate diets. Am. J. Pathol. 1966; 49:
593–603
79. Lieber, CS, DeCarli, LM. Ethanol oxidation by hepatic microsomes:
adaptive increase after ethanol feeding. Science 1968; 162: 417–418
80. Lieber, CS, DeCarli, LM. Hepatic microsomal ethanol oxidizing system: in vitro characteristics and adaptive properties in vivo. J. Biol. Chem. 1970, 245: 2505–2512
81. Tsutsumi, M, Lasker, J M, Shimizu, M, Rosman, AS, Lieber CS. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 1989; 10: 437–446
82. Takahashi, T, Lasker, JM, Rosman, AS, Lieber CS. Induction of cytochrome P4502E1 in the human liver by ethanol is caused by a
corresponding increase in encoding messenger RNA. Hepatology 1993; 17:
236–245
83. Umeno Y, Matsushima E, Maniwa M, Marunaka T. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry. 1988 Dec 13; 27: 9006-9013
84. Salmela KS, Kessova IG, Tsyrlov, IB, Lieber CS. Respective roles of human cytochrome P4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol. Clin. Exp. Res. 1998; 22: 2125–2132
85. Arai M, Leo MA, Nakano M, Gordon ER, Lieber CS. Biochemical and morphological alterations of baboon hepatic mitochondria after chronic ethanol consumption. Hepatology. 1984; 4: 165-74
86. Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 2004; 44: 27-42
87. Cederbaum AI, Wu D, Mari M, Bai J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic Biol Med 2001; 31: 1539-1543
88. Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 2003; 3: 509-518
89. Albano E, Tomasi A, Goria-Gatti L, Dianzani MU, Spin trapping of free radical species produced during the microsomal metabolism of ethanol.
Chem. Biol. Interact. 1988; 65: 223–234
90. Albano E, Tomasi A, Goria-Gatti L, Persson JO, Terelius Y, Ingelman-Sundberg M Dianzani MU. Role of ethanol-inducible cytochrome P-450 (P450IIE1) in catalyzing the free radical activation of aliphatic alcohols.
Biochem. Pharmacol. 1991; 41: 1895–1902
91. Albano E, Parola M, Comoglio A, Dianzani MU, Evidence for the covalent binding of hydroxyethyl radicals to rat liver microsomal proteins. Alcohol Alcohol. 1993; 28: 453–459
92. Tuma DJ, Donohue TM, Medina A, Sorell MF. Acetaldehyde adducts with proteins binding of 14C –acetaldehyde to serum albumin. Arc Biochem.
Biophys 1983; 220: 239-246
93. Stevens VJ, Fantl WF, Newman CB, Sima RV, Cerami A, Peterson CM.
Acetaldehyd adducts with haemoglobin. J. Clin. Invest 1981; 67: 364-369
94. Jennet RB, Sorell MF, Saffari-Ward A, Ockner JL, Tuma DJ. Preferential covalent binding of acetaldehyde to the α-chain of purified rat liver tubulin.
Hepatology 1989; 9: 57-62
95. Viitala K, Israel Y. Blake JE, Niemela O. Serum IgA, IgG and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Hepatology 1997; 25:1418–
1424.
96. Clot P, Albano E, Elliasson, E, Tabone, M, Aricò S, Israel Y, Moncada Y, Ingelman-Sundberg M. Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigenic determinant for autoantibody formation among alcoholics. Gastroenterology 1996; 111: 206–216
97. Albano E, Clot P, Morimoto M, Tomasi A, Ingelman-Sundberg, M, French S. Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radicals in the development of liver damage in rats intragastricaly fed with ethanol. Hepatology1996; 23: 155–163
98. Klassen LW, Tuma D, Sorrell MF. Immune mechanisms of alcohol-induced liver disease. Hepatology 1995; 22: 355–357
99. Xu D, Thiele GM, Beckenhauer JL, Klassen LW, Sorrell MF, Tuma DJ Detection of circulating antibodies to malondialdehyde-acetaldehyde adducts in ethanol-fed rats. Gastroenterology 1998; 115: 686–692
100. Niemelä O, Parkkila S, Pasanen M, Iimuro Y, Bradford B, Thurman RG Early alcoholic liver injury: formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of CYP2E1 and CYP3A.
Alcohol. Clin. Exp. Res. 1998; 22: 2118–2124
101. Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M.
Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J. Hepatol. 2000; 33: 893–901
102. Niemelä O. Aldehyde-protein adducts in the liver as a result of ethanol-induced oxidative stress. Front. Biosci. 1999; 4: d506–d513
103. Niemelä O, Juvonen T, Parkkila S. Immunohistochemical demonstration of acetaldehyde containing epitopes in human liver after ethanol ingestion. J.
Clin. Invest. 1991; 87: 1367–1374
104. Niemelä O, Parkkila S, Ylä-Herttuala S, Halsted CH, Witztum JL, Lanca A, Israel Y. Covalent protein adducts in the liver as a result of ethanol metabolism and lipid peroxidation. Lab. Invest. 1994; 70: 537–546
105. Halsted H, Villanueva J, Chandler CJ, Ruebner B, Munn RJ, Parkkila S, Niemelä O. Centri-lobular distribution of acetaldehyde and collagen in the ethanol-fed micropig. Hepatology 1993; 18: 954–960
106. Niemelä O, Parkkila S, Ylä-Herttuala S, Villanueva J, Ruebner B, Halsted CH. Sequential acetaldehyde production, lipid peroxidation and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995; 22:
1208–1214
107. Niemelä O, Parkkila S, Pasanen M, Iimuro Y, Bradford B, Thurman RG.
Early alcoholic liver injury: formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of CYP2E1 and CYP3A.
Alcohol. Clin. Exp. Res. 1998; 22: 2118–2124
108. Paradis V, Scoazec JY, Kollinger M, Holstege A, Moreau A, Feldmann G, Bedossa P. Cellular and subcellular localization of acetaldehyde-protein adducts in liver biopsies from alcoholic patients. J. Histochem. Cytochem.
1996;44: 1051–1057
109. Trudell R, Ardies CM, Green CE, Allen K. Binding of anti-acetaldehyde IgG antibodies to hepatocytes with an
acetaldehyde-phosphatidylethanolamine adduct on their surface. Alcohol. Clin. Exp. Res.
1991; 15: 295–299
110. Holstege A, Bedossa P, Poynard T, Kollinger M, Chaput JC, Houglum K, Chojkier M. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis. Hepatology 1994; 19: 367–372
111. Baraona E, Matsumura T, Hernandez R, Kubota S, Soong J, Kawano S, Kato S, Inatomi N, Sato S, Lieber CS. Chronic alcohol intake impairs liver oxygenation by decreasing O2 utilization, In K. Kuriyama, A. Takada, & H.
Ishii (Eds.), Biomedical and Social Aspects of Alcohol and Alcoholism:
Proceedings of the Fourth Congress of the International Society for Biomedical Research on Alcoholism: 387–390, Amsterdam, The Netherlands: Elsevier Science Publishers BV 1988
112. Hasumura Y, Teschke R, Lieber CS. Characteristics of acetaldehyde oxidation in rat liver mitochondria. J Biol Chem 1976; 251: 4908–4913
113. Ma X, Baraona E, Lieber CS. Alcohol consumption enhances fatty acid ω-oxidation, with a greater increase in male than in female rats. Hepatology 1993; 18: 1247–1253
114. Koivisto T, Mishin VM, Mak KM, Cohen PA, Lieber, CS. Induction of cytochrome P-4502E1 by ethanol in rat Kupffer cells. Alcohol Clin Exp Res 1996; 20: 207–212.
115. Friedman SL. Stellate cell activation in alcoholic fibrosis-an overview. Alc Clin. Exp. Res. 1999: 23: 904-910
116. Siegmund SV, Dooley S, Brenner DA. Molecular Mechanisms of Alcohol-Induced Hepatic Fibrosis. Dig Dis 2005; 23: 264-274.
117. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 2006; 44:209–216
118. Tazi KA, Moreau R, Herve P, Dauvergne A, cazals-Hatem D, Bert F, Poirel O, Rabiller A, Lebrec D. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005; 129:303–314
119. Tsukamoto H, French SW, Benson N, Delgado G, Rao GA, Larkin EC, Largman C. Severe and progressive steatosis and fibrosis in rat livers induced by intragastric infusion of ethanol and low fat diet. Hepatology 1985; 5: 224-232.
120. http://skatteverket.se/download/18.b7f2d0103e5e9ecb0800074/70407.pdf, accessed May 11th 2006.
121. http://www.socialstyrelsen.se/Statistik/statistik_amne/dodsorsaker/Dödsorsa ksregistret+engelsk.htm, accessed May 11th 2006
122. http://www.socialstyrelsen.se/Statistik/statistik_amne/dodsorsaker/Dödsorsa ksregistret+engelsk.htm, accessed May 11th 2006